Handbook of clinical drug data.pdf - Me and My Life

410 CARDIOVASCULAR DRUGS208. Schultz V et al. Kinetics of elimination of thiocyanate in 7 healthy subjects and in 8 subjects with renal failure.Klin Wochenschr 1979;57:243–7.209. Cottrell JE et al. Prevention of nitroprusside induced cyanide toxicity with hydroxocobalamin. N Engl J Med1978;298:809–11.210. Pasch TH et al. Nitroprusside-induced formation of cyanide and its detoxification with thiosulphate duringdeliberate hypotension. J Cardiovasc Pharmacol 1983;5:77–82.211. Nawarskas JJ, Anderson JR. Omapatrilat. A unique new agent for the treatment of cardiovascular disease.Heart Dis 2000;2:266–74.212. Neutel J et al. Antihypertensive efficacy of omapatrilat, a vasopeptidase inhibitor, compared with lisinopril.J Hypertens 1999;17(suppl 3):S67. Abstract.213. Rouleau JL et al. Vasopeptidase inhibitor or angiotensin converting enzyme inhibitor in heart failure? Resultsof the IMPRESS Trial. Circulation 1999;99(suppl):1847. Abstract.214. McAreavey D, Robertson JI. Angiotensin-converting enzyme inhibitors and moderate hypertension. Drugs1990;40:326–45.215. Salvetti A. Newer ACE inhibitors: a look at the future. Drugs 1990;40:800–28.216. Tenero D et al. Effect of hepatic disease on the pharmacokinetics and plasma protein binding of eprosartan.Pharmacotherapy 1998;18:42–50.217. McClellan KJ, Balfour JA. Eprosartan. Drugs 1998;55:713–8.218. Frishman WH et al. Terazosin: a new long-acting 1-adrenergic antagonist for hypertension. Med Clin NorthAm 1988;72:441–8.219. Stumpf JL. Drug therapy of hypertensive crises. Clin Pharm 1988;7:582–91.220. Hirschl MM. Guidelines for the drug treatment of hypertensive crisis. Drugs 1995;50:991–1000.221. Angaran DM et al. Esmolol hydrochloride: an ultrashort-acting -adrenergic blocking agent. Clin Pharm1986;5:288–303.222. Cuneo BF et al. Pharmacodynamics and pharmacokinetics of esmolol, a short-acting -blocking agent, inchildren. Pediatr Cardiol 1994;15:296–301.223. Trippel DL et al. Cardiovascular and antiarrhythmic effects of esmolol in children. J Pediatr 1991;119(1, pt 1):142–7.224. Routledge PA, Shand DG. Clinical pharmacokinetics of propranolol. Clin Pharmacokinet 1979;4:73–90.225. Nies AS, Shand DG. Clinical pharmacology of propranolol. Circulation 1975;52:6–15.226. Johnsson G, Regardh CG. Clinical pharmacokinetics of -adrenoreceptor blocking drugs. Clin Pharmacokinet1976;1:233–63.227. McTavish D et al. Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeuticefficacy. Drugs 1993;45:232–58.228. MacCarthy EP, Bloomfield SS. Labetalol. A review of its pharmacology, pharmacokinetics, clinical uses andadverse effects. Pharmacotherapy 1983;3:193–219.229. Ryan JR. Clinical pharmacology of acebutolol. Am Heart J 1985;109:1131–6.230. Frishman WH, Covey S. Penbutolol and carteolol: two new beta-adrenergic blockers with partial agonism.J Clin Pharmacol 1990;30:412–21.231. Frishman WH et al. Bevantolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties,and therapeutic efficacy in hypertension and angina pectoris. Drugs 1988;35:1–21.232. Lancaster SG, Sorkin EM. Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokineticproperties, therapeutic efficacy in hypertension and angina pectoris. Drugs 1988;36:256–85.233. Petru MA et al. Long-term efficacy of high-dose diltiazem for chronic stable angina pectoris: 16-month serialstudies with placebo controls. Am Heart J 1985;109:99–103.234. Markham A, Brodgen RN. Diltiazem. A review of its pharmacology and therapeutic use in older patients.Drugs Aging 1993;3:363–90.235. Zelis RF, Kinney EL. The pharmacokinetics of diltiazem in healthy American men. Am J Cardiol1982;49:529–32.236. Joyal M et al. Pharmacodynamic aspects of intravenous diltiazem administration. Am Heart J1986;111:54–60.237. Smith MS et al. Pharmacokinetic and pharmacodynamic effects of diltiazem. Am J Cardiol 1983;51:1369–74.238. Rodriguez I et al. P-glycoprotein in clinical cardiology. Circulation 1999;99:472–4.239. McAllister RG. Kinetics and dynamics of nifedipine after oral sublingual doses. Am J Med 1986;81(suppl6A):2–5.240. Kleinbloesem CH et al. Nifedipine: kinetics and hemodynamic effects in patients with liver cirrhosis afterintravenous and oral administration. Clin Pharmacol Ther 1986;40:21–8.241. Sorkin EM et al. Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeuticefficacy, in ischemic heart disease, hypertension and related cardiovascular disorders. Drugs1985;30:182–274.